Sign in

    Laura Dekker • Edison Group

    Laura Dekker is an Equity Analyst at Edison Group, specializing in the coverage of European healthcare and biotechnology companies. Her research includes detailed analysis of companies such as Avacta Group, Shield Therapeutics, and OptiBiotix Health, with published notes demonstrating deep sector expertise and timely investment recommendations. Dekker began her career in equity research in the early 2010s and joined Edison Group in 2017, having previously held analytical roles at boutique advisory firms. She holds a CFA charter and is registered with the FCA, underscoring her commitment to professional standards and industry best practice.

    Laura Dekker's questions to Telesat Corp (TSAT) leadership

    Laura Dekker's questions to Telesat Corp (TSAT) leadership • Q1 2025

    Question

    Laura Dekker, on behalf of Edison Group, inquired about the current validity of Telesat's long-term revenue and EBITDA targets for the Lightspeed project, which were initially released in late 2023. She asked how the company's perspective on the underlying assumptions has evolved and whether any key variables have significantly changed since the projections were made.

    Answer

    President and CEO Daniel Goldberg confirmed that the previously published projections for Lightspeed's revenue, EBITDA, and CapEx remain the company's current plan. He stated that the constellation's build-out is proceeding on schedule and within budget. Goldberg added that market developments, particularly the growing demand in government services due to geopolitical shifts, have reinforced and even increased their conviction in achieving these financial targets.

    Ask Fintool Equity Research AI